ACLY and autosomal dominant polycystic kidney disease: As outlined above, the purpose of this initial study was to test as a proof of concept the potential role of the ACLY inhibitor and AMPK activator BA as a novel therapeutic for ADPKD using in vitro and in vivo ADPKD model systems.